Corvus Pharmaceuticals, Inc. (CRVS)

NGM – Цена в реальном времени. Валюта: USD

14.01

-0.06 (-0.43%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

14.06

+0.05 (0.36%)

После закрытия: Mar 27, 2026, 7:51 PM EDT

13.03.2026

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript

12.03.2026

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy

05.03.2026

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

23.02.2026

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at Oppenheimer 36th Annual Healthcare Life Sciences Conference which is being held virtually. The presentation will be on Thursday, February 26, 2026 at 2:40pm ET.

02.02.2026

Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026

Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might obscure the fact that a number of individual companies have had a supercharged start to the year, dramatically outperforming the market benchmark.

27.01.2026

Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why

CRVS stock surges 209% in a month after positive cohort 4 phase I data show durable eczema responses for soquelitinib.

27.01.2026

Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know

Does Corvus Pharmaceuticals (CRVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Видео

No Data

There is no data to display

Пресс-релизы

12.03.2026

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy

23.01.2026

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public offering of 9,085,778 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,185,101 additional shares, at a price to the public of $22.15 per share.

22.01.2026

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 shares of its common stock at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $175.0 million. All of the shares of common stock are being offered by Corvus. In addition, Corvus has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,185,101 shares of common stock at the public offering price, less underwriting discounts and commissions.

20.01.2026

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.

Corvus Pharmaceuticals, Inc. (CRVS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026

Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why

Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know

Видео

No Data

Пресс-релизы

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026

Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why

Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know

Видео

No Data

Пресс-релизы

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants